ZL-2401 (Omadacycline) received funding support from National “Significant New Drugs Development Project” Read more about ZL-2401 (Omadacycline) received funding support from National “Significant New Drugs Development Project”
Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) in China as Maintenance Therapy for Patients with Recurrent Ovarian Cancer Read more about Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) in China as Maintenance Therapy for Patients with Recurrent Ovarian Cancer
Zai Lab Announces Upcoming Presentation at 38th Annual J.P. Morgan Healthcare Conference Read more about Zai Lab Announces Upcoming Presentation at 38th Annual J.P. Morgan Healthcare Conference
Zai Lab Announces the Appointment of Timothy Yap, M.D., Ph.D., to its Scientific Advisory Board Read more about Zai Lab Announces the Appointment of Timothy Yap, M.D., Ph.D., to its Scientific Advisory Board
Zai Lab Awarded Commercial Achievement of the Year Read more about Zai Lab Awarded Commercial Achievement of the Year
Zai Lab Announces Upcoming Presentations at November Conferences Read more about Zai Lab Announces Upcoming Presentations at November Conferences
Zai Lab Partner, MacroGenics, Announces Initiation of Phase 2/3 MAHOGANY Study of Margetuximab in Gastric or Gastroesophageal Junction Cancer Read more about Zai Lab Partner, MacroGenics, Announces Initiation of Phase 2/3 MAHOGANY Study of Margetuximab in Gastric or Gastroesophageal Junction Cancer
Zai Lab Partner, GSK, Announces U.S. Food and Drug Administration Approval of Additional Indication for Zejula (niraparib) for Late-line Treatment for Women with Recurrent Ovarian Cancer Read more about Zai Lab Partner, GSK, Announces U.S. Food and Drug Administration Approval of Additional Indication for Zejula (niraparib) for Late-line Treatment for Women with Recurrent Ovarian Cancer
Dr. Samantha Du, Zai Lab Founder and CEO, to Participate in Forbes Global CEO Conference Read more about Dr. Samantha Du, Zai Lab Founder and CEO, to Participate in Forbes Global CEO Conference
Phase 3 PRIMA trial of Zejula® (niraparib) is the first study to show a PARP inhibitor significantly improves PFS, regardless of biomarker status, when given as monotherapy in women with first-line platinum responsive advanced ovarian cancer Read more about Phase 3 PRIMA trial of Zejula® (niraparib) is the first study to show a PARP inhibitor significantly improves PFS, regardless of biomarker status, when given as monotherapy in women with first-line platinum responsive advanced ovarian cancer